2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
12:00 p.m. - 01:30 p.m.
MCCNO - 208-210
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Blood Banking, Computational Biology, Treatment Considerations, Supportive Care, Biological Therapies, Transfusion, Infusion, Non-Biological Therapies, Women’s Health, Artificial Intelligence (AI), Machine Learning, Biological Processes, CHIP, Genomics, Clinical Practice (Health Services and Quality), Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Thrombocytopenias, Bone Marrow Failure Syndromes, Immunology, Neutropenia, Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult
PAPER

638 Implementation of an integrated Duffy antigen testing pathway improves diagnostic stewardship for neutropenia evaluation

Olisaemeka Ogbue, MBBS, Ayo Samuel Falade, MD, MBA2, Joselle M Cook, M.D.3, Jeffrey Winters, MD4, Ronald Go, MD5, Justin Juskewitch, MD, PhD6, Richard C. Godby, MD7
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States

Background:

Duffy-null associated neutrophil count (DANC) is a benign cause of neutropenia associated with the Duffy-null [Fy(a−b−)] phenotype and no increased infection risk. Underrecognition frequently leads to unnecessary diagnostic evaluation, particularly among individuals of African and Middle Eastern ancestry. We evaluated whether an electronic health record (EHR)-integrated Duffy antigen testing pathway with standardized interpretive guidance could reduce unnecessary testing, healthcare utilization, and diagnostic costs during neutropenia evaluation.

Methods: On April 17, 2025, the Special Red Cell Antigen Typing order was redesigned to include a dedicated indication for suspected DANC, targeted Fya/Fyb antigen phenotyping, and standardized interpretive comments. We performed a retrospective pre-post study of patients undergoing Duffy antigen testing during the year before and after implementation. The primary outcome was the total number of diagnostic investigations per patient. Secondary outcomes included utilization of individual investigations, healthcare utilization, hematology referrals, diagnostic yield, and healthcare costs. Investigations and encounters were identified using linked ICD/CPT codes. Costs were estimated using 2025 CMS reimbursement rates and institutional direct costs for specialized procedures. Fisher's exact and Mann–Whitney U tests were used.

Results: A total of 170 consecutive patients were included (81 pre-implementation and 89 post-implementation; median age 49 years [IQR, 33-59], 60% female). The cohort was racially and ethnically diverse (41% White, 37% African American, 7% Hispanic, 3% Asian, and 11% Other), with similar baseline characteristics between study periods. Duffy antigen testing was ordered predominantly by Hematology (145/170, 85%). The Duffy-null phenotype was identified in 46% of patients overall and in N=60 (94%) of African American patients. Consistent with DANC, Duffy-null patients had lower mean absolute neutrophil counts than non-null patients (1.21 vs. 1.64 ×10³/µL, p=0.014).

Diagnostic stewardship improved significantly following implementation. The median number of diagnostic investigations per patient decreased from 3 to 2 (Mann–Whitney p=0.0049). Bone marrow biopsy utilization declined from 27% to 13% (p=0.034), nutritional evaluation from 69% to 53% (p=0.041), and abdominal imaging from 15% to 3% (p=0.013). Peripheral flow cytometry (28% vs. 17%, p=0.097) and autoimmune testing (57% vs. 42%, p=0.065) also declined.

The intervention shifted Duffy antigen testing earlier in the diagnostic pathway, improving diagnostic efficiency. Before testing, the mean number of non-hematology clinical encounters per patient decreased from 1.40 to 0.20 (p<0.001), while the mean number of hematology visits before testing decreased from 0.75 to 0.11 (p<0.001). The mean number of hematology follow-up visits after testing also decreased from 1.06 to 0.67 (p=0.022), whereas hematology referral rates remained unchanged (89% vs. 82%, p=0.28).

Median diagnostic cost per patient decreased substantially ($535 [IQR, $71–16,389] vs. $101 [IQR, $0–512]; p=0.0036). Mean diagnostic cost per patient also decreased by 49% ($5,359 vs. $2,742). Total diagnostic expenditures decreased by 44%, from $434,078 to $244,070 (absolute savings $190,008), with avoided bone marrow biopsies accounting for 86% of savings, followed by imaging (9%) and sequencing (3%). Cost reduction remained significant after excluding bone marrow biopsy costs ($940 vs. $549 per patient; p=0.013).

Importantly, reducing diagnostic investigations did not compromise diagnostic yield. Detection of clinically significant alternative diagnoses was preserved (10/81 [12%] vs. 16/89 [18%], p=0.35). Overall, clinically significant diagnoses were identified in 15% of patients, most commonly autoimmune neutropenia (n=7), acquired bone marrow failure disorders including clonal cytopenia of undetermined significance (CCUS; n=5), myeloid neoplasms (n=4), and plasma cell neoplasms (n=2).

Conclusions: An EHR-integrated Duffy antigen testing pathway significantly improved diagnostic stewardship by reducing unnecessary investigations, healthcare utilization, and diagnostic costs while preserving detection of clinically significant disease. This scalable intervention provides a practical strategy to improve equitable neutropenia evaluation and can be readily adopted across healthcare systems.

Olisaemeka Ogbue, MBBS: No relevant conflicts of interest to declare.